Making Your Decision

The right question is not "should I take hormone therapy?" It is: which specific treatment, delivered how, at what dose, at what point in your transition, makes sense for your situation? The answer depends on individual factors — your symptoms, your medical history, your risk profile, and your preferences — and those factors can change the treatment calculus in opposite directions.

This section maps the decision factors that matter most. For the treatment options themselves, see the Treatment Options section. For specific symptom domains, see the relevant later sections.

Route and Formulation Affect Safety

One important qualification: a large Swedish study (919,614 women) found that estrogen patch used as part of a combined hormone regimenⓘ still carried a VTE signal (HR 1.46-1.67), while estrogen patch alone (without a progestogen)ⓘ did not. "Transdermal is safer" is not a complete statement — route, the specific progestogen, and the specific outcome (clotting vs stroke vs arterial disease) all need to be separated. The Long-Term Health section breaks this down in detail.

In women with type 2 diabetes at low cardiovascular risk, estrogen pill (estradiol)ⓘ showed advantages for glucose metabolism (33) — the opposite direction from the cardiovascular route preference. Which route is best depends on which risk dominates your individual profile.

If You Have a Breast Cancer History

Breast cancer history changes the decision framework entirely — and the specifics depend on what kind of breast cancer.

ER-positive breast cancer: In the cited expert-panel framework (25-member modified Delphi, 88), systemic MHT after ER-positive breast cancer is treated as higher-risk, especially within 5-10 years of diagnosis, with magnitude proportional to background risk. The panel reached 100% agreement that combining systemic estrogen with an aromatase inhibitor is counterproductive. The panel discusses rare off-label consideration only through careful shared decision-making — if systemic MHT is chosen, a low-dose estrogen patch with natural progesteroneⓘ is the formulation discussed.

ER-negative breast cancer: The expert-panel framework treats relapse risk differently after ER-negative disease because residual cells lack estrogen receptors. However, there is approximately a 1% per year risk of a second breast cancer, roughly half of which are ER-positive. Estrogen-only therapy may decrease second-cancer risk in limited data.

DCIS (ductal carcinoma in situ): The expert-panel framework considers DCIS differently from invasive breast cancer — DCIS is usually curable, and the risk-benefit balance may differ. However, direct MHT safety data after DCIS are absent — no studies have evaluated this specifically. One additional consideration: hormone therapy can increase mammographic density, which decreases screening sensitivity — a concern separate from the direct recurrence question.

For all three subgroups, the decision framework is the same: weigh symptom severity and quality-of-life impact against individual relapse risk, with patient preferences central to the conversation. The Breast Cancer & HRT section covers the evidence in full.

Treating menopausal symptoms may also protect cancer treatment adherence. The same expert panel reached 100% agreement that patients are more likely to continue their adjuvant endocrine therapy (tamoxifen, aromatase inhibitors) when menopausal side effects are managed. Non-adherence to these cancer treatments worsens breast cancer outcomes — so treating menopausal symptoms is not separate from cancer care; it supports it (88).

If You Have Premature Ovarian Insufficiency or Early Menopause

In women with POI (before age 40) or early menopause (ages 40-45), the decision logic is fundamentally different. Guidelines generally frame hormone therapy as primary prevention — for cardiovascular disease, type 2 diabetes, and osteoporosis — rather than symptom-only treatment, even when symptoms are mild or absent. Doses are higher than standard menopause treatment, and therapy continues until the usual age of natural menopause (~50). Contraindications are narrower than in standard menopause care, with estrogen-sensitive cancer a key exception. See the Special Populations section for full dosing and monitoring guidance (60).

Timing and Duration

When hormone therapy is started matters. Early initiation — within 10 years of menopause or before age 60 — is associated with a more favorable cardiovascular benefit-risk profile (4). Guideline discussions commonly emphasize lower effective dosing, shorter duration, and transdermal route when initiation is later.

Contraception During the Transition

If you are still having periods or are within 1-2 years of your last period, contraception remains necessary. Options include the hormonal IUDⓘ (which also provides endometrial protection if you are using estrogen), progestogen-only implants, and combined pills with body-identical estrogen — which can provide symptom relief and contraception together. Injectable contraceptives are generally used only until about age 50 due to bone density concerns (53).

Bone Health Without Symptoms

If you have no menopausal symptoms but are concerned about bone loss, the decision is less clear-cut. Guidelines lack consensus on when hormone therapy might be indicated purely for bone-loss prevention in asymptomatic women — this is a gap area where shared decision-making applies (27). What the evidence does show: hormone therapy reduces fracture risk regardless of fall risk or baseline FRAX score, and non-hormonal vasomotor symptom treatments do not provide bone protection (53). If bone health is your primary concern and you have no symptoms driving a treatment decision, this is a conversation about prevention strategy, not symptom management.

Inherited VTE Susceptibility

The Progestogen Matters Too

Most discussion of hormone therapy focuses on estrogen. But if you have a uterus and take estrogen, you also need a progestogen for endometrial protection — and the type of progestogen affects mood, sleep, breast cancer risk, and cardiovascular/metabolic outcomes independently. Micronized progesterone and dydrogesterone often show more favorable profiles than several synthetic progestins across these domains, but the best choice depends on the specific comparator, route, population, and outcome being considered. The formulation-dependence framework applies to both the estrogen and the progestogen component of any hormone therapy regimen.

Questions to Bring to Your Doctor

• "Given my medical history, which specific formulation, route, and dose are you recommending — and what evidence supports that choice for someone in my situation?"
• "I had [ER+/ER-/DCIS] breast cancer. What does the current evidence say about hormone therapy for my specific subtype?"
• "I'm considering starting hormone therapy [early in my transition / later]. How does timing affect the risk-benefit balance for me?"
• "Do I still need contraception? If so, is there an option that also helps with my menopausal symptoms?"
• "I don't have symptoms but I'm concerned about bone health. Is there evidence for starting treatment purely for prevention?"
• "Do I have any risk factors — family history of clots, metabolic conditions, specific cancer history — that should change which route or formulation we choose?"